The Global Hemophilia Drugs Market

1
The Global Hemophilia Drugs Market covered the
value of US 9875.4 Mn in the year 2017 and is
anticipated to reach US 15830.3 Mn by 2025.
Furthermore, the global market for hemodialysis
is expected to report a CAGR of 6.0 during the
forecast period. The above information was
published in a report, titled Hemophilia Drugs
Market Size, Share and Global Trend by Disease
Indication (Hemophilia A, B C), Therapy Type
(Recombinant Therapy, Plasma therapy Others),
Distribution Channels (Hospital Pharmacy, Retail
Pharmacy, Online Pharmacy) and Geography
Forecast till 2025. The rising prevalence of
severe diseases is one of the major concerns in
the healthcare industry. Among these disorders,
patients with hemophilia suffer from an abnormal
blood loss and this weakens their blood clotting
process. Companies are introducing novel
hemophilia drugs and therapies to fulfill the
unmet needs of patients and maintain their
quality of life. Request Sample PDF
at https//www.fortunebusinessinsights.com/enquiry
/request-sample-pdf/hemophilia-drugs-
market-100068 A lead analyst at Fortune Business
Insights said, Companies are building expansion
strategies to develop new hemophilia drugs so as
toa offer a better diagnosis.Among disease
indications, hemophilia A is projected to
exhibit strong growth in the coming years. In
addition to this, this segment covered a share
of 85 in the global hemophilia drugs market in
2017. This is mainly attributable to the rising
pool patients suffering from hemophilia across
the world. Also, rising initiatives at
developing and commercializing new products for
the effective treatment of hemophilia is driving
this segments growth. Following hemophilia A,
hemophilia B drugs are also expected to grow at
a considerable rate in the years to come. The
Asia Pacific to Grow at a Rapid Pace with Rising
Number of Hemophilia Patients North America is
projected to emerge dominant in the global
hemophilia drugs market during the forecast
period. This is mainly ascribable to the rising
prevalence of hemophilia A and B, especially in
countries such as Canada and the U.S. Moreover,
in 2017, North America market for hemophilia
drugs covered a value of US 3,684.7 Mn. Trailing
North America, Europe is the second-leading
region in the global hemophilia drugs market. The
growth in this region is attributable to the
rising healthcare budgets by governments and
initiatives by governments to promote hemophilia
drugs treatment. On the other hand, the
hemophilia drugs market in the Asia Pacific is
likely to expand at a higher CAGR between 2017
and 2025 on account of the rising number of
patients suffering from hemophilia especially in
countries such as China and India. Browse
Complete Report Details https//www.fortunebusines
sinsights.com/industry-reports/hemophilia-drugs-ma
rket-100068
2
Rising Awareness About Hemophilia to Augment the
Demand The primary factor augmenting the
hemophilia drugs market is the recent
developments in hemophilia treatment. A lead
analyst at Fortune Business Insights said
Several new drugs are expected to enter the
global market in the coming years. Also,
hemophilia surgical management is gaining
traction on account of increasing awareness about
hemophilia across the world. Moreover,
governments are planning to conduct awareness
initiatives to spread knowledge regarding the
use of hemophilia treatment and drugs This, in
turn, is expected to drive the hemophilia drugs
market over the next few years. The genetic
evolution is leading to rising incidences of
bleeding disorders across the world. This will
further lead to hemophilia drug development in
the next few years to come. As per the study
conducted by the National Hemophilia Foundation
or NHF in 2015, about 1 of the U.S. population
is likely to suffer from a disease called von
Willebrand, hence rising the need for hemophilia
treatment drugs. Pfizer Introduced Gene Therapy
to Address Unmet Patients Needs Some of the
leading players presently operating in the global
market for hemophilia drugs are Grifols SA,
Bioverativ Inc., FERRING LÄKEMEDEL AB, Aptevo
Therapeutics, Hoffmann-La Roche Ltd, Novo
Nordisk, Pfizer, Inc., and CSL Behring. In 2018,
companies such as Novo Nordisk, Takeda
Pharmaceutical Company Ltd., and F. Hoffmann-La
Roche Ltd covered more than half of the share in
the global hemodialysis market as per revenue. In
2017, Pfizer, Inc. collaborated with Sangamo
Therapeutics, Inc. to commercialize and develop
gene therapy programs. The aim was to utilize
these programs for Hemophilia A drugs. Speak to
Analyst https//www.fortunebusinessinsights.com/en
quiry/speak-to-analyst/hemophilia-drugs-
market-100068 About us Fortune Business
Insights offers expert corporate analysis and
accurate data, helping organizations of all
sizes make timely decisions. We tailor innovative
solutions for our clients, assisting them to
address challenges distinct to their businesses.
Our goal is to empower our clients with holistic
market intelligence, giving a granular overview
of the market they are operating in. Our
reports contain a unique mix of tangible insights
and qualitative analysis to help companies
achieve sustainable growth. Our team of
experienced analysts and consultants use
industry- leading research tools and techniques
to compile comprehensive market studies,
interspersed with relevant data.
3
At Fortune Business Insights we aim at
highlighting the most lucrative growth
opportunities for our clients. We therefore
offer recommendations, making it easier for them
to navigate through technological and
market-related changes. Our consulting services
are designed to help organizations identify
hidden opportunities and understand prevailing
competitive challenges. Contact us Fortune
Business Insights Pvt. Ltd. 308, Supreme
Headquarters, Survey No. 36, Baner, Pune-Bangalor
e Highway, Pune - 411045, Maharashtra, India.
Phone US 1 424 253 0390 UK 44 2071
939123 APAC 91 744 740 1245 Email
sales_at_fortunebusinessinsights.com